Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells
Sign Up to like & getrecommendations! Published in 2021 at "Nucleic Acids Research"
DOI: 10.1093/nar/gkab1173
Abstract: Abstract Cockayne syndrome group B (CSB) protein has been implicated in the repair of a variety of DNA lesions that induce replication stress. However, little is known about its role at stalled replication forks. Here,… read more here.
Keywords: brca1 deficient; csb; fork; deficient cells ... See more keywords
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer research"
DOI: 10.1158/0008-5472.can-16-2350
Abstract: There remains great interest in practical strategies to limit the elevated risks of familial breast and ovarian cancers driven by BRCA1 mutation. Here, we report that limiting the production of reactive oxygen species (ROS) is… read more here.
Keywords: breast; breast cancer; model; brca1 deficient ... See more keywords
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-4024
Abstract: Purpose: BRCA1-deficient breast cancers carry a specific DNA copy-number signature (“BRCA1-like”) and are hypersensitive to DNA double-strand break (DSB) inducing compounds. Here, we explored whether (i) EZH2 is overexpressed in human BRCA1-deficient breast tumors and… read more here.
Keywords: brca1 like; based chemotherapy; platinum; brca1 deficient ... See more keywords
Abstract 333: USP1 is required for replication fork stability in BRCA1-deficient tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-333
Abstract: Homologous-recombination (HR) deficient tumors with BRCA1 and BRCA2 mutations exhibit replication fork stability defects. To date, PARP inhibitors are the only targeted therapy available in the clinic against HR deficient tumors, and alternative therapies are… read more here.
Keywords: replication fork; deficient tumors; brca1 deficient; fork ... See more keywords
Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-045
Abstract: Transcriptional dysregulation promotes R-loops and impairs homologous recombination in Ewing sarcoma. read more here.
Keywords: ewing sarcomas; deficient tumors; phenocopy brca1; brca1 deficient ... See more keywords
Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Theranostics"
DOI: 10.7150/thno.18563
Abstract: Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we… read more here.
Keywords: breast cancer; sustained release; brca1 deficient; talazoparib ... See more keywords